Neotherix is delighted to announce the award of £25k by the Technology Strategy Board (TSB) for a four month feasibility study. The new project will develop Neotherix electrospun scaffolds to incorporate additional anti-cancer functionality for regenerative medicine applications.
This project will explore the feasibility of combining a selection of anti-cancer drugs with Neotherix' proprietary electrospun scaffold technology to create new advanced regenerative medicine products for therapeutic applications. As the number of applications and technologies for regenerative medicine continue to grow, there will be an increasing demand for such functional materials that are capable of carrying out multiple roles during tissue repair.
This investment in Neotherix follows a successful proposal made to the TSB's Technology-Inspired Innovation competition in the Advanced Materials and Nanoscale Technologies technology category. Neotherix is one of 71 SMEs awarded funding to carry out feasibility studies in the across a broad range of technology areas, as part of a wider £20m investment in these growth-creating technologies by the TSB, Scottish Enterprise and the Biotechnology and Biological Sciences Research Council.
Please see the TSB competition announcement web page or download the TSB press release for more information.